NORTH CHICAGO, Ill., Oct. 28, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and ...

- Seven abstract presentations showcase ongoing research in presbyopia and glaucomaNORTH CHICAGO, Ill., April 28, 2022 /PRNewswire/ -- Allergan, ...

--Allergan Aesthetics and Allergan, an AbbVie company, announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical ...

Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol. PR Newswire. NORTH CHICAGO, Ill., June 26, 2020.

--Allergan, an AbbVie company, today announced new data to be presented from Allergan's leading portfolio of eye care treatments at the 2022 American Glaucoma Society Annual Meeting being held in ...

NORTH CHICAGO, Ill., April 28, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new data on VUITY ™ (pilocarpine HCl ophthalmic solution) 1.25%, the ...

NORTH CHICAGO, Ill., April 19, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new data from its leading eye care portfolio at the 2022 American ...

NORTH CHICAGO, Ill., April 28, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new data on VUITY ™ (pilocarpine HCl ophthalmic solution) 1.25%, the ...